Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2016 08:30 ET | Source: Enzymotec Ltd.

Enzymotec to Report First Quarter 2016 Financial Results

MIGDAL HA'EMEQ, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients...
March 29, 2016 08:30 ET | Source: Enzymotec Ltd.

Enzymotec Ltd. Granted Patents in U.S. for Compositions and Processes Related to Infant Nutrition and China for INFAT® Uses Promoting Development of Beneficial Gut Flora and Reducing Infant Crying Duration

MIGDAL HA'EMEQ, Israel, March 29, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients...
March 16, 2016 08:30 ET | Source: Enzymotec Ltd.

InCog™, Enzymotec's Innovative Lipid Composition for Cognitive Functioning, Enhances Brain Development and Improves Survival in Preclinical Study

MIGDAL HA'EMEQ, Israel, March 16, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (NASDAQ:ENZY) (“Company” or "Enzymotec"), a developer, manufacturer and marketer of innovative bio-active lipid based...
March 08, 2016 16:30 ET | Source: Enzymotec Ltd.

Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2015

MIGDAL HA’EMEQ, Israel, March 08, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) (“Company”), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional...
February 17, 2016 09:07 ET | Source: Enzymotec Ltd.

CORRECTING and REPLACING -- Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results

Fourth Quarter Non-GAAP Net Income* of $0.07 per Diluted Share Inclusive of $0.05 for Accelerated Growth Initiative Spend VAYA Pharma Generates Record Net Revenues of $2.3 Million in the Quarter...
February 17, 2016 07:30 ET | Source: Enzymotec Ltd.

Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results

Fourth Quarter Non-GAAP Net Income* of $0.07 per Diluted Share Inclusive of $0.05 for Accelerated Growth Initiative Spend VAYA Pharma Generates Record Net Revenues of $2.3 Million in the Quarter...
February 03, 2016 08:30 ET | Source: Enzymotec Ltd.

Enzymotec to Report Fourth Quarter and Full Year 2015 Financial Results

MIGDAL HA'EMEQ, Israel, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods,...
February 02, 2016 08:30 ET | Source: Enzymotec Ltd.

Enzymotec Announces Positive Outcome in ICC Arbitration Award

Arbitration tribunal rejects AAK’s requests for declaratory relief in their entirety Finds in accordance with Enzymotec’s position that the joint venture agreement may be terminated only through...
January 04, 2016 08:00 ET | Source: Enzymotec Ltd.

Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31, 2019

MIGDAL HA’EMEQ, Israel, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) (the “Company”), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional...
December 21, 2015 08:30 ET | Source: Enzymotec Ltd.

Enzymotec Granted Mexican Patent for INFAT® Uses Related to Promoting Intestinal Health

MIGDAL HA'EMEQ, Israel, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients...